Slit2-Robo1 Signaling Activates Ras to Suppress Metastasis and Is Associated with Time-To-Progression in Pancreatic Neuroendocrine Tumors Abstract #1736

Introduction: Transcriptom analysis revealed that mRNA signatures of distinct metastatic phenotypes in pancreatic NETs (pNETs) exhibit differences in components of the Slit-Robo pathway.
Aim(s): Delineating the role of Slit2 and its receptor Robo1 for pNET progression.
Materials and methods: Expression analysis in human pNETs was determined by IHC and qPCR. Migration, colony formation, and metastasis of mouse orthotopic pNETs were evaluated using pNET cells with restored Slit2 expression or Robo1 inactivation.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. med. Christian Fischer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#770 The Axon Guidance Molecules Slit2 and Robo Control Motility and Growth of Pancreatic Neuroendocrine Tumor Cells
Introduction: Dense vascularization and high frequency of metastasis in pancreatic neuroendocrine tumors (pNET) suggest a central role for the interaction of tumor cells and vessels. Slit2 and its receptors Robo1 and Robo4 act as guidance cues in neurogenesis, angiogenesis and epithelial morphogenesis, and hence represent attractive candidate regulators at the tumor cell/stroma interface.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Christian Fischer
#1539 Slit-Robo Signaling Links to Ras Activity to Suppress Metastasis and Is Associated with Time-to-Progression in Pancreatic Neuroendocrine Tumors
Introduction: mRNA signatures of distinct metastatic phenotypes of pancreatic NETs (pNETs) exhibit differences in several components of the Slit-Robo axon guidance system.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. med. Christian Fischer
#1395 A Single Centres Experience of Cardiac Metastasis from Neuroendocrine Tumours (NET)
Introduction: Cardiac metastasis from NET are rare with little information to guide management strategies. Previous case reports discuss varying strategies including observation, somatostatin analogues (SSA), chemotherapy, radiotherapy and resection.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Burge M, Wyld D, ...
#1861 Surgical Strategies and Selection Criteria for Patients with Liver Metastasis from Neuroendocrine Tumors: Personal Experience.
Introduction: The role of surgical treatment of liver metastasis from neuroendocrine neoplasm(NET) is still a debated issue,and the management of these patients is entrusted to the practical experience of single centers.The main problem is that there are not available randomized trials comparing surgical resection to unthreated patients or other liver directed therapy.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Dr Bruno Pauletti
#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr. med. Georgi Atanasov